Market Overview:
The global eculizumab market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of PNH, aHUS, and other diseases that are treated with eculizumab. Additionally, the increasing awareness about these diseases and growing demand for better treatment options are also contributing to the growth of this market. The global eculizumab market is segmented on the basis of type, application, and region. On the basis of type, it is divided into plasma exchange and plasma infusion. The plasma exchange segment dominates this market owing to its high usage in treating various diseases such as PNH, aHUS, and others. On the basis of application, it is divided into PNH (paroxysmal nocturnal hemoglobinuria), aHUS (atypical hemolytic uremic syndrome), other applications (including myasthenia gravis [MG], thrombotic thrombocytopenic purpura [TTP], chronic kidney disease [CKD], glomerulonephritis [GN]), North America (the U.S., Canada), Latin America (Brazil Mexico), Europe (Germany France Italy Spain United Kingdom Rest Of Europe), Asia Pacific excluding Japan) Japan) Middle East & Africa).
Product Definition:
Eculizumab is a medication used to treat the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). It binds to C5, preventing it from being cleaved to release the potent inflammatory mediators C5a and C5b-9. These cytokines are responsible for tissue damage in PNH and aHUS.
Plasma Exchange:
Plasma exchange is a medical procedure wherein blood is drawn from the patient and then replaced with fresh blood. This process helps in removing proteins, cells, and other harmful substances from the body. It also helps in boosting up the immune system by increasing white blood cell count.
The global eculizumab market size was valued at USD 785 million in 2016 and it is expected to grow at a CAGR of XX% over the forecast period.
Plasma Infusion:
Plasma infusion is a procedure wherein blood is removed from the donor and replaced with an artificial solution in the patient's body. It helps in increasing the amount of protein, vitamins, minerals and other essential components in a human body. Plasma infusion has various benefits such as it increases strength, energy level and even improves memory loss problems caused due to old age or disease process.
Application Insights:
The other applications segment dominated the global eculizumab market in 2017, accounting for over 60% share of the total revenue. The segment includes PNH, aHUS and others. Eculizumab is approved for treatment of patients with PNH who have not responded to other therapies such as chemotherapy or phototherapy. It is also approved for use in patients with aHUS and severe chronic kidney disease (CKD).
In September 2017, Biogen Inc., partnered with CSL Ltd., an Australian biopharmaceutical company to develop medicines that target HLA-matched grafts and stem cells in the bone marrow transplantation setting. This collaboration would enable access to innovative cell therapy products through CSL's proprietary cell isolation technology known as Stem Cells On Demand (SDoD).
Regional Analysis:
North America dominated the global eculizumab market in 2017. The presence of key players, favorable reimbursement scenario, and increasing awareness levels are some of the factors responsible for its largest share. In addition, growing healthcare expenditure by governments along with a rise in prevalence is expected to drive growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to an increase in disease burden coupled with rising disposable income and improved access to health care facilities especially outside major markets such as India & China & Japan. Moreover, government initiatives promoting better healthcare outcomes at lower costs are expected fuel regional demand during the forecast period (2018-2030). For instance; ‘Healthcare Financing Administration’ (HFA) project initiated by WHO which provides country specific recommendations for effective financing strategies that enable high-quality health services delivery has been implemented in Asia Pacific since 2014.
Growth Factors:
- Increasing incidence of hemolytic uremic syndrome (HUS)
- Rising demand for better and more effective treatments for HUS
- Growing awareness about eculizumab as a treatment option for HUS
- Availability of government funding for eculizumab therapy in some countries
- Launch of new and improved versions of eculizumab
Scope Of The Report
Report Attributes
Report Details
Report Title
Eculizumab Market Research Report
By Type
Plasma Exchange, Plasma Infusion
By Application
PNH, aHUS, Other
By Companies
Alexion
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
237
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Eculizumab Market Report Segments:
The global Eculizumab market is segmented on the basis of:
Types
Plasma Exchange, Plasma Infusion
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
PNH, aHUS, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Alexion
Highlights of The Eculizumab Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Plasma Exchange
- Plasma Infusion
- By Application:
- PNH
- aHUS
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Eculizumab Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Eculizumab is a monoclonal antibody that binds to the interleukin-17 receptor (IL-17R). It is used to treat moderate to severe plaque psoriasis. Eculizumab may also be used for other conditions as determined by your doctor.
Some of the major companies in the eculizumab market are Alexion.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Eculizumab Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Eculizumab Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Eculizumab Market - Supply Chain
4.5. Global Eculizumab Market Forecast
4.5.1. Eculizumab Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Eculizumab Market Size (000 Units) and Y-o-Y Growth
4.5.3. Eculizumab Market Absolute $ Opportunity
5. Global Eculizumab Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Eculizumab Market Size and Volume Forecast by Type
5.3.1. Plasma Exchange
5.3.2. Plasma Infusion
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Eculizumab Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Eculizumab Market Size and Volume Forecast by Application
6.3.1. PNH
6.3.2. aHUS
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Eculizumab Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Eculizumab Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Eculizumab Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Eculizumab Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Eculizumab Demand Share Forecast, 2019-2026
9. North America Eculizumab Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Eculizumab Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Eculizumab Market Size and Volume Forecast by Application
9.4.1. PNH
9.4.2. aHUS
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Eculizumab Market Size and Volume Forecast by Type
9.7.1. Plasma Exchange
9.7.2. Plasma Infusion
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Eculizumab Demand Share Forecast, 2019-2026
10. Latin America Eculizumab Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Eculizumab Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Eculizumab Market Size and Volume Forecast by Application
10.4.1. PNH
10.4.2. aHUS
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Eculizumab Market Size and Volume Forecast by Type
10.7.1. Plasma Exchange
10.7.2. Plasma Infusion
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Eculizumab Demand Share Forecast, 2019-2026
11. Europe Eculizumab Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Eculizumab Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Eculizumab Market Size and Volume Forecast by Application
11.4.1. PNH
11.4.2. aHUS
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Eculizumab Market Size and Volume Forecast by Type
11.7.1. Plasma Exchange
11.7.2. Plasma Infusion
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
1110.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Eculizumab Demand Share, 2019-2026
12. Asia Pacific Eculizumab Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Eculizumab Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Eculizumab Market Size and Volume Forecast by Application
12.4.1. PNH
12.4.2. aHUS
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Eculizumab Market Size and Volume Forecast by Type
12.7.1. Plasma Exchange
12.7.2. Plasma Infusion
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Eculizumab Demand Share, 2019-2026
13. Middle East & Africa Eculizumab Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Eculizumab Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Eculizumab Market Size and Volume Forecast by Application
13.4.1. PNH
13.4.2. aHUS
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Eculizumab Market Size and Volume Forecast by Type
13.7.1. Plasma Exchange
13.7.2. Plasma Infusion
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Eculizumab Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Eculizumab Market: Market Share Analysis
14.2. Eculizumab Distributors and Customers
14.3. Eculizumab Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Alexion
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. COMPANY2
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. COMPANY3
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. COMPANY4
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
